Investor Presentation Full Year 2021

5 Investor presentation Full year 2021 Sales growth of 14% driven by both operating units and by all therapy areas Reported geographic sales split for the full year 2021 Reported therapy area sales and growth for the full year 2021 North America Operations billion Growth at CER DKK billion Insulin Obesity care GLP-1 Other diabetes DKK Biopharm Growth at CER 80 14% International Operations Novo Nordisk® 160 14% 32% 1% 55% 4% 14% 140 60 60 International Operations 120 14% 100 40 40 12% 80 60 20 20 19% 11% 52% IO 3% 40 6% 14% IO 52% NAO 6% 20 25% NAO 57% -9% 0 0 ΙΟ EMEA China ROW NAO Total1 GLP-1 Insulin Obesity Biopharm 1 'Other diabetes' is included in Total IO: International Operations; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations Note: Unless otherwise specified, sales growth rates are at CER

View entire presentation